Arix portfolio firm Amplyx extends its series C funding
20th May 2020 10:24
(Sharecast News) - Venture capital company Arix Bioscience noted on Wednesday that its portfolio company, Amplyx Pharmaceuticals, has closed a $53m (£43.22m) series C extension.
Read moreArix Bioscience net asset value slides amid 'volatility' in holdings
10th Mar 2020 11:49
(Sharecast News) - Biotechnology venture capital company Arix Bioscience reported a year-end net asset value of ?202m in its annual results on Tuesday, or 149p per share, equating to a 25% decline in net asset value per share for the year, compared to a 32% increase in 2018.
Read moreArix Bioscience portfolio firm Imara files for US IPO
17th Feb 2020 10:21
(Sharecast News) - Biotechnology investor Arix Bioscience announced on Monday that one of its portfolio companies, Imara, has filed a registration statement with the United States Securities and Exchange Commission (SEC) for a proposed initial public offering in the US, of shares of its common stock.
Read moreFinance chief Rawlingson steps down from Arix Bioscience
2nd Oct 2019 08:53
(Sharecast News) - Biotechnology-focussed venture capital company Arix Bioscience announced the departure of its chief financial officer James Rawlingson on Wednesday.
Read moreArix Bioscience business LogicBio files for US IPO
26th Sep 2018 13:59
(Sharecast News) - Healthcare and life science company Arix Bioscience announced on Wednesday that one of its group businesses, genome editing company LogicBio Therapeutics, has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering in the United States.
Read moreArix buys small chunk of Australia's Pharmaxis
6th Aug 2018 15:12
(Sharecast News) - Healthcare and life science company Arix Bioscience has acquired an 11% interest in Australian pharmaceutical research company Pharmaxis, it announced on Monday.
Read moreArix raises £100m in oversubscribed IPO
17th Feb 2017 11:05
(ShareCast News) - Life sciences company Arix has successfully raised £100m in its oversubscribed initial public offering, which comprised 48.31m shares. Based on the offer price, Arix's total market capitalisation at admission would be £187m. "This new capital enables us to continue our commitment
Read more